Cevimeline Hydrochloride 30 mg/1

Cevimeline Hydrochloride, the active ingredient in Cevimeline Hydrochloride 30 mg, is a muscarinic receptor agonist presented as a 30 mg capsule for oral use. It is used to treat symptoms of dry mouth in patients with Sjögren's syndrome, a condition that affects the immune system and causes dryness in certain parts of the body such as the eyes and mouth.

GNH USA supplies Cevimeline Hydrochloride 30 mg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Cevimeline Hydrochloride is a muscarinic receptor agonist used to treat symptoms of dry mouth associated with Sjögren's syndrome and other conditions that reduce saliva production.

- Sjögren's syndrome: Increases saliva production to alleviate dry mouth symptoms. - Radiation-induced xerostomia: Helps manage dry mouth caused by radiation therapy. - Other autoimmune conditions: May be used to treat dry mouth in conditions similar to Sjögren's syndrome.

Cevimeline Hydrochloride may cause various side effects, ranging from common to serious. Common Side Effects: - Excessive sweating - Nausea - Runny nose (rhinitis) - Diarrhea - Headache - Dizziness - Blurred vision

Serious or Rare Side Effects: - Severe nausea or vomiting - Indigestion or stomach pain - Itchy skin - Light-colored stools - Yellow eyes or skin - Bloody or cloudy urine - Pain in the lower back or side - Chest pain or tightness - Irregular heartbeat - Swelling of the face, fingers, feet, or lower legs

Cevimeline Hydrochloride should be used with caution in certain patient populations and conditions. Always follow your healthcare provider's advice and the prescribed dosage.

- Asthma, uncontrolled: Contraindicated in patients with uncontrolled asthma. - Hypersensitivity: Not recommended for patients with known hypersensitivity to cevimeline. - Acute iritis: Avoid use in patients with acute iritis or narrow-angle glaucoma. - Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease. - Pulmonary disease: Administer with caution in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease (COPD). - Ocular effects: May cause visual blurring, especially at night or in reduced lighting. - Store at room temperature: Keep in the original container, tightly closed, and away from moisture and light.

Cevimeline Hydrochloride may interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Major Interactions (Avoid): - Beta-blockers: May exacerbate cardiovascular effects. - Anticholinergic drugs: May reduce the effectiveness of cevimeline. - Drugs that increase bronchial secretions: May worsen respiratory conditions.

Moderate Interactions (Monitor Closely): - Cardiovascular medications: May alter heart rate or rhythm. - Ophthalmic medications: May cause visual disturbances. - Drugs affecting gastrointestinal motility: May increase the risk of gastrointestinal side effects.